Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTOR-II: C1-esterase inhibitor during human endotoxemia
2011-002222-46Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of C1 inhibitor, human in Systemic Inflammatory Response Syndrome (SIRS) and endotoxemia (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Neutrophil phenotype after LPS with and without C1-esterase inhibitor. Started Mar 2013; status: completed.
02
Drugs
C1 inhibitor, human
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)endotoxemia
Beyond the preview
Go deeper on 2011-002222-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002222-46.